Maze Therapeutics, Inc. (MAZE) Gets a Buy from TD Cowen
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The company's shares closed today at $9.06.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Van Buren is an analyst with an average return of -5.2% and a 36.16% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Travere Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Maze Therapeutics, Inc. with a $25.67 average price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Those who invested in BrightSpire Capital (NYSE:BRSP) three years ago are up 2.0%
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the risk of stock picking is that you will likely buy under-performing companies. Unfortunately, that's been the case for longer term BrightSpire Capital, Inc. (NYSE:BRSP) shareholders, since the share price is down 29% in the last three years, falling well short of the market return of around 64%. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. BrightSpire Capital wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. In the last three years, BrightSpire Capital saw its revenue grow by 0.5% per year, compound. Given it's losing money in pursuit of growth, we are not really impressed with that. Indeed, the stock dropped 9% over the last three years. If revenue growth accelerates, we might see the share price bounce. But ultimately the key will be whether the company can become profitability. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). Take a more thorough look at BrightSpire Capital's financial health with this free report on its balance sheet. It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of BrightSpire Capital, it has a TSR of 2.0% for the last 3 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence! BrightSpire Capital shareholders are up 1.5% for the year (even including dividends). Unfortunately this falls short of the market return. It's probably a good sign that the company has an even better long term track record, having provided shareholders with an annual TSR of 5% over five years. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. It's always interesting to track share price performance over the longer term. But to understand BrightSpire Capital better, we need to consider many other factors. Case in point: We've spotted 1 warning sign for BrightSpire Capital you should be aware of. Of course BrightSpire Capital may not be the best stock to buy. So you may wish to see this free collection of growth stocks. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Business Insider
30 minutes ago
- Business Insider
Petra Capital Sticks to Its Buy Rating for Silver Mines Limited (SWQ)
Petra Capital analyst Andrew Richards CFA maintained a Buy rating on Silver Mines Limited (SWQ – Research Report) today and set a price target of A$0.17. The company's shares closed last Tuesday at €0.08. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Richards CFA is a 4-star analyst with an average return of 25.4% and an 88.24% success rate. Richards CFA covers the Basic Materials sector, focusing on stocks such as Medallion Metals Ltd, Silver Mines Limited, and Metro Mining Limited. Silver Mines Limited has an analyst consensus of Moderate Buy, with a price target consensus of €0.10.
Business Insider
30 minutes ago
- Business Insider
Petra Capital Sticks to Their Buy Rating for Austin Engineering (AUSTF)
In a report released today, James Lennon from Petra Capital maintained a Buy rating on Austin Engineering (AUSTF – Research Report), with a price target of A$0.59. The company's shares closed yesterday at $0.25. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Lennon is a 4-star analyst with an average return of 14.4% and a 48.44% success rate. Lennon covers the Industrials sector, focusing on stocks such as Austin Engineering , Austal , and Bhagwan Marine Ltd.. Currently, the analyst consensus on Austin Engineering is a Moderate Buy with an average price target of $0.46, implying an 81.60% upside from current levels. In a report released yesterday, Shaw and Partners also maintained a Buy rating on the stock with a A$0.60 price target.
